SPG6 supports development of acute myeloid leukemia by regulating BMPR2-Smad-Bcl-2/Bcl-xl signaling

被引:3
|
作者
Chen, Jinliang [1 ]
Li, Chunling [1 ]
Zhan, Renhui [2 ]
Yin, Yancun [1 ]
机构
[1] Binzhou Med Univ, Sch Basic Med Sci, Taishan Scholar Immunol Program, 346 Guanhai Rd, Yantai 264003, Shandong, Peoples R China
[2] Binzhou Med Univ, Med & Pharm Res Ctr, Yantai 269003, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
SPG6; Acute myeloid leukemia; BMPR2; Apoptosis; HEREDITARY SPASTIC PARAPLEGIA; IMMUNOGLOBULIN-LIKE RECEPTORS; STEM-CELLS; CANCER DEVELOPMENT; TGF-BETA; PROTEINS; NIPA1; EXPRESSION; TARGET; BMPR2;
D O I
10.1016/j.bbrc.2018.04.220
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Acute myeloid leukemia (AML) is the most common acute leukemia affecting adults. To effectively treat AML, new molecular targets and therapeutic approaches must be identified. In silico analysis of several available databases of AML patients showed that the expression of Spastic Paraplegia 6 Protein (SPG6) significantly inversely correlates with the overall survival of AML patients. To determine whether SPG6 supports AML development, we employed an shRNA-encoding lentivirus system to inhibit SPG6 expression in human AML cells including NB4 and MV4-11 cells. Knockdown expression of SPG6 resulted in decreased cell growth and elevated apoptosis of these leukemia cells. Notably, the SPG6 deficiency resulted in higher BMPR2 expression indicating that BMPR2 signaling contributes to AML pathogenesis. Furthermore, SPG6 deficiency promoted phosphorylation of Smad1/5/9 and decreased transcription of BcI-2 and Bcl-xl. Our study suggests that SPG6 contributes to AML pathogenesis, and suggests that inhibition of SPG6 may be novel strategy for treating human AML. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:220 / 225
页数:6
相关论文
共 50 条
  • [1] a Selective Bcl-2 Inhibitor with Tuned Bcl-Xl Activity, Causes Myeloid Differentiation and Cell Death in Acute Myeloid Leukemia (AML)
    Koenig, Kristin L.
    Brame, Colin
    Sher, Steven
    Beaver, Larry
    Cempre, Casey B.
    Williams, Katie
    Purcell, Matthew
    Harrington, Bonnie
    Chen, Yi
    Tan, Felai
    Anthony, Stephen P.
    Chen, Yu
    Shen, Yue
    Byrd, John C.
    Lapalombella, Rosa
    BLOOD, 2022, 140 : 9068 - 9069
  • [2] Bcl-2 and Bcl-xL Suppress Glucose Signaling in Pancreatic β-Cells
    Luciani, Dan S.
    White, Sarah A.
    Widenmaier, Scott B.
    Saran, Varun V.
    Taghizadeh, Farnaz
    Hu, Xiaoke
    Allard, Michael F.
    Johnson, James D.
    DIABETES, 2013, 62 (01) : 170 - 182
  • [3] Expression of inducible bcl-XS in myeloid leukemia -: Compensatory Upregulation of Bcl-XL and bcl-2 prevents apoptosis and chemosensitization
    Tacke, F
    Marini, FC
    Zhao, SR
    McQueen, T
    Konopleva, M
    Ruvolo, PP
    Hu, SX
    Xu, HJ
    Andreeff, M
    CANCER BIOLOGY & THERAPY, 2004, 3 (03) : 340 - 347
  • [4] Concurrent targeting Bcl-2/Bcl-xL and MDM2 as a new therapeutic strategy for acute leukemia
    Hoffman-Luca, C. Gianna
    McEachern, Donna
    Ziazadeh, Daniel
    Zhao, Yu-Jun
    Sun, Wei
    Debussche, Laurent
    Wang, Shaomeng
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [5] Bcl-XL Is a Critical Mediator of Rac Signaling in MLL-AF9-Induced Acute Myeloid Leukemia
    Mizukawa, Benjamin
    Wei, Junping
    Wunderlich, Mark
    Chou, Fu-Sheng
    Zheng, Yi
    Williams, David A.
    Mulloy, James C.
    BLOOD, 2009, 114 (22) : 780 - 781
  • [6] CXCR4 Chemokine Receptor Signaling Induces Apoptosis in Acute Myeloid Leukemia Cells via Regulation of the Bcl-2 Family Members Bcl-XL, Noxa, and Bak
    Kremer, Kimberly N.
    Peterson, Kevin L.
    Schneider, Paula A.
    Meng, X. Wei
    Dai, Haiming
    Hess, Allan D.
    Smith, B. Douglas
    Rodriguez-Ramirez, Christie
    Karp, Judith E.
    Kaufmann, Scott H.
    Hedin, Karen E.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (32) : 22899 - 22914
  • [7] Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
    Kuusanmaki, Heikki
    Dufva, Olli
    Vaha-Koskela, Markus
    Leppae, Aino-Maija
    Huuhtanen, Jani
    Vanttinen, Ida
    Nygren, Petra
    Klievink, Jay
    Bouhlal, Jonas
    Polonen, Petri
    Zhang, Qi
    Adnan-Awad, Shady
    Mancebo-Perez, Cristina
    Saad, Joseph
    Miettinen, Juho
    Javarappa, Komal K.
    Aakko, Sofia
    Ruokoranta, Tanja
    Eldfors, Samuli
    Heinaniemi, Merja
    Theilgaard-Monch, Kim
    Wartiovaara-Kautto, Ulla
    Keranen, Mikko
    Porkka, Kimmo
    Konopleva, Marina
    Wennerberg, Krister
    Kontro, Mika
    Heckman, Caroline A.
    Mustjoki, Satu
    BLOOD, 2023, 141 (13) : 1610 - 1625
  • [8] Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia
    Dufva, Olli
    Kuusanmaki, Heikki
    Vaha-Koskela, Markus
    Leppa, Aino-Maija
    Huuhtanen, Jani
    Vanttinen, Ida
    Nygren, Petra Johanna
    Klievink, Jay
    Bouhlal, Jonas
    Polonen, Petri
    Zhang, Qi
    Awad, Shady Adnan
    Mancebo, Cristina
    Saad, Joseph
    Miettinen, Juho J.
    Javarappa, Komal Kumar
    Aakko, Sofia
    Ruokoranta, Tanja
    Eldfors, Samuli
    Heinaniemi, Merja
    Wartiovaara-Kautto, Ulla
    Konopleva, Marina
    Keranen, Mikko A.
    Porkka, Kimmo
    Wennerberg, Krister
    Kontro, Mika
    Heckman, Caroline A.
    Mustjoki, Satu
    BLOOD, 2022, 140
  • [9] Apoptosis of human myeloid leukemia cells induced by an inhibitor of protein phosphatases (okadaic acid) is prevented by Bcl-2 and Bcl-XL
    A Benito
    A Lerga
    M Silva
    J Leon
    JL Fernandez-Luna
    Leukemia, 1997, 11 : 940 - 944
  • [10] Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines
    Nuessler, V
    Stötzer, O
    Gullis, E
    Pelka-Fleischer, R
    Pogrebniak, A
    Gieseler, F
    Wilmanns, W
    LEUKEMIA, 1999, 13 (11) : 1864 - 1872